HMTXF Stock — Hemostemix Inc

Hemostemix Inc (HMTXF)

Updated October 16, 2026.

HMTXF is a Stock. Total return is -99.7% over the past 10.8 years, 467.4 points behind SPY at 367.7%.

Hemostemix Inc. is a clinical-stage biotechnology company developing blood-derived stem cell therapies for conditions including peripheral arterial disease, chronic limb-threatening ischemia, and vascular dementia; its lead candidate, ACP-01, has completed Phase II trials, while a second program, NCP-01, is in preclinical development. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotech innovation, though clinical-stage companies carry substantial development and regulatory risk with no guarantee of eventual commercialization.

HMTXF performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.7% over the past 10.8 years, 467.4 points behind SPY at 367.7%. Over the past year its total return — price change plus distributions reinvested — is -46.1%. Its deepest 1-year drawdown was 54.1%.

HMTXF key facts

Asset type

Stock

Asset class

Equity

Inception date

01/07/2016

Distribution frequency

None

Last close

$0.04 (as of 2026-10-16)

Market cap

$8,478,801

Average volume

24463.0

Payment date

12/30/2020

Beta

0.666

Payout ratio

0.0%

EPS

$-0.02

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HMTXF risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 54.1%.

Who may consider HMTXF — and who may not

It is a weaker fit for investors who need monthly cash flow (HMTXF does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on HMTXF

• All tickers starting with H

Tagged: Healthcare.

Frequently asked questions